Spot Trading’s Avadel Pharmaceuticals AVDL Stock Holding History

Spot Trading’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-20,800	Closed	-$254K	–	3428
2015 Q4	$254K	Buy	+20,800	New	+$324K	﹤0.01%	2336

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Spot Trading's AVDL Position: Q4 2016 in Review

Spot Trading sold out of Avadel Pharmaceuticals (AVDL) in Q4 2016, closing a stake of 2,900 shares — an estimated $36K sold.

Spot Trading first reported a position in AVDL in Q2 2016 and held it in 2 quarters. The position peaked at $75K in Q2 2016. 76 funds tracked by Wall St. Rank hold AVDL as of Q4 2016.

Spot Trading reported no remaining Avadel Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Spot Trading sold 2,900 Avadel Pharmaceuticals shares in Q4 2016, an estimated $36K.
Spot Trading first reported a position in Avadel Pharmaceuticals in Q2 2016 and held it in 2 quarters.
Spot Trading's Avadel Pharmaceuticals position peaked at $75K in Q2 2016.
76 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.